Digital Biomarkers Market Overview
The global Digital Biomarkers Market is entering a period of rapid expansion as healthcare organizations, pharmaceutical companies, and clinical researchers increasingly use wearable devices, mobile technologies, sensors, and digital platforms to capture continuous patient data.
According to MarketsandMarkets™, the global digital biomarkers market is projected to grow from approximately USD 7.41 billion in 2026 to USD 17.73 billion by 2031, registering a CAGR of 19.1% during 2026–2031.
The increasing adoption of remote monitoring, decentralized clinical trials, real-world data, and digital endpoints is creating significant opportunities for digital biomarker technologies across multiple therapeutic areas.
Digital Biomarkers Market at a Glance
- 2026 Market Size: USD 7.41 billion
- 2031 Projected Market Size: USD 17.73 billion
- CAGR (2026–2031): 19.1%
- Market Size Available: 2025–2031
- Largest Type Segment: Physiological biomarkers
- Largest Therapeutic Area: Cardiovascular
- Leading Region: North America
Download PDF Brochure – MarketsandMarkets™
What Are Digital Biomarkers?
Digital biomarkers are measurable, objective data collected through digital technologies such as smartphones, wearable devices, connected sensors, and other digital health platforms.
These technologies can continuously capture parameters such as:
- Heart rate
- Heart rhythm
- Physical activity
- Sleep patterns
- Respiratory rate
- Blood oxygen levels
- Movement and gait
- Cognitive performance
- Behavioral patterns
- Patient-reported digital signals
Unlike traditional biomarkers that may require laboratory testing or periodic clinical assessments, digital biomarkers can provide high-frequency data in real-world settings.
Key Trends Driving the Digital Biomarkers Market
1. Growing Adoption in Clinical Research
Clinical research is one of the most important growth areas for digital biomarkers. Pharmaceutical companies and clinical research organizations are increasingly using digital technologies to capture patient data remotely and continuously.
Digital endpoints can provide researchers with more frequent measurements compared with traditional clinical visits. This can support assessment of treatment response, disease progression, patient adherence, and functional outcomes.
The clinical research applications segment is expected to experience significant growth during the forecast period as clinical trials increasingly incorporate remote data capture, digital endpoints, and wearable technologies.
Digital biomarkers are being explored across therapeutic areas including cardiology, neurology, endocrinology, psychiatry, oncology, and respiratory diseases.
2. Expansion of Wearable and Sensor Technologies
Wearable technologies are becoming an important source of digital biomarker data. Smartwatches, fitness trackers, ECG devices, biosensors, and connected medical devices can capture physiological and behavioral information outside conventional healthcare environments.
The growing availability of these technologies is helping researchers collect real-world, longitudinal datasets while reducing the need for frequent in-person assessments.
3. Growth of Decentralized Clinical Trials
The increasing adoption of decentralized and hybrid clinical trial models is creating additional demand for digital biomarkers.
Remote monitoring technologies can allow participants to contribute data from their homes, reducing travel requirements and potentially improving patient participation and retention.
Digital biomarkers can therefore support:
- Remote patient monitoring
- Continuous endpoint collection
- Real-world evidence generation
- Patient engagement
- Treatment adherence monitoring
- Longitudinal disease assessment
4. Increasing Use of AI and Data Analytics
The growing volume of data generated by wearable and connected devices is increasing demand for advanced analytics and artificial intelligence.
AI and machine learning can help transform raw sensor data into clinically meaningful insights. These technologies may assist with pattern recognition, anomaly detection, risk prediction, and identification of changes in patient physiology.
The combination of AI + wearable sensors + cloud platforms + digital biomarkers is expected to become increasingly important in precision medicine and clinical research.
Digital Biomarkers Market Segmentation Insights
By Type: Physiological Biomarkers Lead
The physiological biomarkers segment accounted for 40.6% of the digital biomarkers market in 2025, representing the largest share by type.
Physiological biomarkers can be derived from measurements such as heart rate, ECG, respiratory activity, blood oxygen levels, temperature, and physical activity.
The increasing availability of wearable and connected devices capable of continuously monitoring these parameters is supporting segment growth.
As sensor technology improves, physiological data can increasingly be collected outside hospitals and laboratories, providing researchers and healthcare professionals with more comprehensive longitudinal information.
Cardiovascular Segment Holds the Largest Therapeutic-Area Share
The cardiovascular segment accounted for the largest share of the digital biomarkers market in 2025.
Cardiovascular diseases remain a major global health burden, creating substantial demand for continuous monitoring and early detection technologies.
Digital biomarkers can capture cardiovascular signals such as:
- Heart rate
- Heart rhythm
- ECG
- Heart-rate variability
- Physical activity
- Sleep-related parameters
Wearable ECG technologies and connected cardiovascular monitoring devices are increasingly being investigated for applications such as atrial fibrillation detection and cardiovascular risk monitoring.
The availability of continuous physiological data makes cardiovascular medicine particularly suitable for digital biomarker applications.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=7725399
North America Leads the Digital Biomarkers Market
North America accounted for approximately 48.1% of the global digital biomarkers market in 2025.
The region’s strong position is supported by:
- Advanced digital health infrastructure
- High adoption of wearable technologies
- Strong pharmaceutical and biotechnology industries
- Large-scale clinical research activity
- Growing use of remote patient monitoring
- Increasing adoption of digital endpoints
- Presence of technology and digital-health companies
- Strong investment in healthcare innovation
The US, in particular, represents an important market because of its extensive clinical trial ecosystem and growing integration of digital technologies into clinical research.
Major research institutions and healthcare organizations are increasingly exploring digital endpoints and remote monitoring technologies, supporting the broader development of the digital biomarkers ecosystem.
Digital Biomarkers in Clinical Trials
Digital biomarkers are increasingly becoming an important component of modern clinical trial design.
Traditional clinical trials often depend on periodic assessments conducted at healthcare facilities. Digital technologies can supplement these assessments by capturing patient information continuously or at much higher frequencies.
For researchers, this can provide additional insights into:
- Disease progression
- Treatment effectiveness
- Treatment adherence
- Patient behavior
- Functional outcomes
- Physiological changes
- Quality-of-life indicators
The ability to collect real-world data remotely can also support more patient-centric clinical trial models.
Digital Biomarkers and Remote Patient Monitoring
Remote patient monitoring represents another major application area.
Connected devices can transmit physiological information to healthcare professionals or research platforms, enabling continuous observation of patients outside conventional healthcare settings.
This approach is particularly relevant to chronic diseases where ongoing monitoring may provide valuable information between clinical visits.
Digital biomarkers can potentially support earlier identification of clinically meaningful changes and help healthcare providers make more informed decisions.
Major Companies in the Digital Biomarkers Market
The digital biomarkers market includes technology companies, digital health providers, medical device manufacturers, and clinical research technology companies.
Key companies include:
- IXICO PLC
- Ametris, LLC
- Empatica, Inc.
- AliveCor, Inc.
- CONNEQT Health
- VivoSense
- BioSensics
- Lunit, Inc.
- Akili, Inc.
- Quibim
- Clario
- Proscia, Inc.
- Koneksa Health
- Linus Health
These companies are focusing on digital endpoints, wearable sensors, AI-powered analytics, remote monitoring, neurological assessment, cardiovascular monitoring, and clinical trial technologies.
Future Outlook for Digital Biomarkers
The future of digital biomarkers is closely connected to the continued digitalization of healthcare and clinical research.
The combination of wearables, biosensors, smartphones, AI, cloud computing, and real-world data analytics is expected to create increasingly sophisticated methods for measuring health and disease.
Future developments are likely to focus on:
- AI-powered digital endpoints
- Continuous physiological monitoring
- Multimodal biomarker platforms
- Remote and decentralized clinical trials
- Personalized medicine
- Digital phenotyping
- Real-world evidence
- Predictive health analytics
- Automated clinical-trial data collection
As regulatory frameworks, data standards, interoperability, and analytical methodologies continue to develop, digital biomarkers could become an increasingly important component of evidence generation and patient monitoring.
Conclusion
The digital biomarkers market is undergoing rapid transformation, driven by the convergence of digital health, wearable technology, artificial intelligence, remote monitoring, and clinical research.
With the market projected to increase from USD 7.41 billion in 2026 to USD 17.73 billion by 2031 at a CAGR of 19.1%, significant opportunities exist for technology developers, pharmaceutical companies, clinical research organizations, healthcare providers, and digital health platforms.
Physiological biomarkers currently represent a major market segment, while cardiovascular applications and clinical research are expected to remain important areas of adoption. Meanwhile, North America’s established digital-health and clinical-research ecosystem continues to support its leadership position.
The next phase of digital biomarker development is likely to focus on turning continuous streams of real-world data into validated, clinically meaningful insights that can support more efficient clinical research and increasingly personalized healthcare.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=7725399